Bod Science has published additional positive results from a pharmacokinetics (PK) study of its Aqua Phase technology, showing the platform delivers six times greater bioavailability compared to oil-based CBD.
The ethics-approved Phase 1 study recruited 12 healthy volunteers, who were fasted before receiving either a 100mg Aqua Phase CBD dose or 100mg of CBD in oil under tightly controlled conditions.
The analysis found bioavailability increased by more than 530% (6.3 times), with maximum concentration coming in 270% (3.7 times) higher than oil-based CBD. Peak concentration was achieved at 2.5 hours, compared to six hours with oil.
An earlier study, completed in July 2023, measured the bioavailability of CBD complexed with Aqua Phase in capillary blood, whereas the most recent research evaluated the technology using venous blood.
Both studies produced consistent findings, though the venous blood study recorded significantly higher bioavailability. Bod has now concluded the research and development work required to support the technology's commercialisation.
The company said the outcomes "support the commercial opportunities of the technology as a preferred oral-dose format, solving solubility and bioavailability limitations of water-hating molecules".
CEO Jo Patterson added: "We are pleased with the results from this second PK study as they further support the exciting properties of Aqua Phase as a unique product delivery process technology.
"The results verify the value proposition. Aqua Phase holds a broader opportunity for drugs that have solubility and bioavailability limitation, not being limited to the cannabis sector."
Bod identified the pharmaceutical, nutraceuticals and beverage markets as further potential commercial avenues for the technology, which it acquired from two UK scientists for A$5 million in a deal first announced in August 2022.
